CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

CRISPR Therapeutics (CRSP) shares have rallied 41.4% over the past three months, driven by encouraging Phase I data for its in-vivo candidate CTX310, which demonstrated significant reductions in LDL and TG, and robust Q2 2025 sales of Casgevy, which surged to $30.4 million, reflecting a 114.1% sequential increase. This accelerating commercial momentum for Casgevy, coupled with a diversified early-stage gene-editing pipeline and a new RNA therapeutics collaboration, is providing a strong revenue base to fund future development, positioning CRSP favorably despite competitive pressures and the early-stage nature of many pipeline assets.

Analysis

CRISPR Therapeutics (CRSP) has experienced a significant 41.4% stock price rally over the past three months, driven by tangible progress on both commercial and clinical fronts. The primary commercial catalyst is the accelerating sales momentum of Casgevy, its gene therapy for sickle cell disease and beta-thalassemia, developed with partner Vertex Pharmaceuticals. After a slow start, Casgevy sales reached $30.4 million in Q2 2025, a 114.1% sequential increase, signaling strong market adoption with over 75 treatment centers activated and 115 patients initiating the process. This revenue growth is crucial as it begins to establish a reliable funding base for the company's extensive pipeline. Clinically, the company reported encouraging Phase I data for its in-vivo candidate CTX310, which demonstrated dose-dependent reductions in LDL and triglycerides of up to 86% and 82%, respectively. This result helps de-risk CRISPR's in-vivo gene-editing platform. Despite these positives, the company faces a competitive landscape, with Intellia Therapeutics appearing more advanced in the in-vivo space and Beam Therapeutics developing a competing SCD therapy. Financially, CRSP maintains a strong cash position of $1.7 billion, but analyst estimates show a widening loss per share for 2025, contrasted by a narrowing loss for 2026, indicating significant near-term R&D investment with an eye towards future profitability.

Key Decisions for Investors

• Given the stock's 41.4% recent rally, investors should closely monitor Casgevy's sales trajectory in the upcoming quarters to validate that the commercial ramp-up is sustainable and can support the company's valuation.
• Pay close attention to upcoming clinical data readouts later in 2025 for CAR-T candidates CTX112 and CTX131, as positive results would further validate the breadth of CRISPR's platform beyond Casgevy.
• Investors should hedge or manage position size based on competitive milestones, particularly updated data from Beam Therapeutics' BEACON study by year-end 2025 and Intellia's planned regulatory filing in H2 2026, which could shift the competitive dynamics in the gene-editing space.
• While the stock trades at a price-to-book discount to the industry, the widening 2025 loss estimates suggest caution regarding near-term cash burn, making the company's $1.7 billion cash reserve a critical metric to track against operational spending.